Collage style hand holding semaglutide Injection Pen cost or money concept with textures and vibrant colors. GLP-1RAs
Credit: JDawnInk /Getty Images

Researchers have discovered reasons why some people are more likely than others to lose weight when taking glucagon-like peptide-1 receptor agonists (GLP-1RAs). The findings could help create personalized treatments that maximize the benefits of treatment with drugs such as semaglutide, which is sold as Ozempic and Wegovy.

The research revealed that longer treatment, initial use with semaglutide, not having diabetes and having a higher proportion of body fat were all linked to better weight loss over the course of a year.

Other factors that boded well included a higher basal metabolic rate as well as greater skeletal muscle mass, muscle mass in the abdomen and limbs, and serum creatinine levels.

The study appears in the journal Diabetes, Obesity and Metabolism.

“These findings may provide novel insights into the weight fluctuations after GLP-1RA treatment in the real-world setting, thereby advancing the development of individualized strategies with GLP-1RA therapy for patients with overweight or obesity,” said co–corresponding author Linong Ji, PhD, from Peking University People’s Hospital in Beijing, China.

GLP-1RA is a revolutionary medication in the global fight against obesity, not only for its effectiveness in weight loss but also for the benefits it provides in terms of blood glucose regulation, and cardiovascular and renal protection.

In a retrospective study, the team studied characteristics that affect its efficacy among 679 patients who were overweight or obese and initiated GLP-1RAs at the obesity and weight loss clinic of the Peking University People’s Hospital between November 2022 and October 2024.

During 12 months of follow up, successful weight reduction was associated with a longer duration of GLP-1RA treatment (odds ratio [OR]=1.01) and higher Homeostasis Model Assessment of β-Cell Function (HOMA-β) levels (OR=4.91).

At six-month follow-up, successful weight loss was associated with non-diabetic status (OR=2.18) and using semaglutide (OR=2.14).

In addition, successful weight loss was associated with a higher percentage body fat in both men (OR=3.99) and women (OR=2.27).

Patients who regained weight had a higher baseline estimated glomerular filtration rate than those whose weight remained stable or had successful weigh loss at the three-month follow-up, particularly for those with prediabetes.

There were J-shaped associations between basal metabolic rate, skeletal muscle mass, abdominal and limb muscle mass and the likelihood of successful weight loss within six months.

There was also a positive non-linear association between serum creatinine with the chances of successful weight reduction within 12 months.

“To our knowledge, this is one of the comprehensive studies depicting weight fluctuations among individuals with overweight or obesity after GLP-1RA treatment in a real-world setting,” the authors reported.

They added: “Our findings emphasize the critical role of high medication adherence and persistence in GLP-1RA treatment, which indicates the need for enhanced adherence monitoring in clinical practice.

“Furthermore, the different treatment responses across participants with different diabetes/prediabetes statuses and glycemic control parameters highlight the necessity for metabolic state-adapted therapeutic strategies.”